(Q24241443)

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir prophylaxis of herpes-simplex-virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral Acyclovir for Prevention of Herpes Simplex Virus Reactivation After Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Prospective randomized trial of antibiotic prophylaxis in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Acyclovir prophylaxis for herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Implementation and evaluation of a standardized herpes simplex virus prophylaxis protocol on a leukemia/bone marrow transplant unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Use of levamisole in viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

21 January 2018

Antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Management of acyclovir-resistant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Quality of life and oral function following radiotherapy for head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

Penciclovir cream--improved topical treatment for herpes simplex infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

INOSIPLEX IN RECURRENT HERPES SIMPLEX INFECTIONS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient host: results after a 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

7 January 2021

Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

7 January 2021

[Use of acyclovir in the prevention of herpes infections after allogenic bone marrow grafts]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

7 January 2021

Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006706.PUB2

7 January 2021